Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Xuanzhu Biopharmaceutical Co., Ltd.
軒竹生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2575)

VOLUNTARY ANNOUNCEMENT COMPLETION OF ENROLLMENT OF ALL SUBJECTS IN PHASE III CLINICAL TRIAL IN CHINA OF ANAPRAZOLE SODIUM ENTERIC-COATED TABLETS (AN JIU WEI) FOR THE TREATMENT OF REFLUX ESOPHAGITIS

The board of directors (the "**Board**") of Xuanzhu Biopharmaceutical Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the phase III clinical trial in China of the innovative drug Anaprazole Sodium Enteric-coated Tablets (trade name: An Jiu Wei) independently developed by the Company for the treatment of adult reflux esophagitis ("**RE**") has successfully completed the enrollment of all 500 subjects recently.

This phase III clinical trial is a multi-centre, randomized, double-blind, double-dummy, active-drug parallel-controlled pivotal study designed to evaluate the efficacy and safety of Anaprazole Sodium Enteric-coated Tablets in the treatment of Chinese adult subjects with RE. The primary clinical endpoint of the trial is the endoscopic healing rate of RE in subjects after a predetermined treatment cycle compared with the active control drug (within 8 weeks of treatment (including 8 weeks)); the secondary endpoints cover multiple efficacy indicators including the endoscopic healing rate of RE in subjects (at week 4 of treatment), changes from baseline in severity and frequency of major symptoms (heartburn and regurgitation) (at week 4 and week 8 of treatment). The safety indicators mainly include the types, incidence rates, and severity of adverse events.

ABOUT ANAPRAZOLE SODIUM ENTERIC-COATED TABLETS

Anaprazole Sodium Enteric-coated Tablets (trade name: An Jiu Wei) was approved for marketing by the National Medical Products Administration of China in June 2023 for the treatment of patients with duodenal ulcer. Anaprazole Sodium features an innovative structural design with characteristics including non-enzymatic plus multi-enzymatic metabolism and balanced intestinal-renal dual-channel excretion, with only 3.5% metabolized through CYP2C19, making it unaffected by CYP2C19 gene polymorphism. Compared with previous generations of proton pump inhibitors, Anaprazole Sodium has lower risk of drug-drug interactions, making it a safer choice for patients on multiple medications and those with renal impairment, and is a proton pump inhibitor more suitable for the Chinese population. As a Class 1 innovative drug in China, Anaprazole Sodium fills the gap in domestically developed proton pump inhibitors, bringing treatment options with both superior efficacy and safety to Chinese patients. In addition to the approved indication for duodenal ulcer, the phase III clinical study in China of Anaprazole Sodium Enteric-coated Tablets for the treatment of RE was fully launched in July 2025, and has recently successfully completed the enrollment of all 500 subjects.

This announcement is a voluntary announcement made by the Company for the purpose of keeping the broad investors informed of the latest business development of the Group, and does not contain any advertisement or intention regarding the use of any drug, surgical device, treatment or oral product.

By order of the Board
Xuanzhu Biopharmaceutical Co., Ltd.
Ms. Xu Yanjun
Chairperson of the Board and executive Director

Hong Kong, 22 March 2026

As of the date of this announcement, the board of directors of the Company comprises (i) Ms. Xu Yanjun, Dr. Li Jia Kui and Dr. Shih Cheng-Kon as executive Directors; (ii) Ms. Li Huiying, Mr. Yu Lifeng and Ms. Chen Yanling as non-executive Directors; and (iii) Mr. Liu Shuo, Ms. Wang Yu and Mr. Fan Chi Chiu as independent non-executive Directors.